A novel breast/ovarian cancer peptide vaccine platform that promotes specific type-1 but not treg/tr1-type responses

Journal of Immunotherapy

Volumn 33, Issue 3, 2010, Pages 250-261

  Karkada, Mohan ^a,b   Weir, Genevieve M ^a   Quinton, Tara ^a   Sammatur, Leeladhar ^a   Macdonald, Lisa D ^a   Grant, Alecia ^a   Liwski, Robert ^b   Juskevicius, Ridas ^b   Sinnathamby, Gomathinayagam ^c   Philip, Ramila ^c   Mansour, Marc ^a  

^a ImmunoVaccine Technologies Inc   (Canada)

^b DALHOUSIE UNIVERSITY   (Canada)

^c Immunotope Inc   (United States)

Author keywords

Breast cancer; DepoVax; GM CSF; Liposome; Regulatory T cells

Indexed keywords

CANCER VACCINE; DEPOVAX; DPX 0907; EPITOPE; GAMMA INTERFERON; HLA A2 ANTIGEN; INTERLEUKIN 10; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; TRANSCRIPTION FACTOR FOXP3; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST CANCER; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL EXPANSION; CONTROLLED STUDY; DRUG EFFICACY; EMULSION; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOFLUORESCENCE; LYMPH NODE; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; OVARY CANCER; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; SPLEEN; TUMOR CELL LINE;

AMINO ACID SEQUENCE; ANIMALS; BREAST NEOPLASMS; CANCER VACCINES; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE, TUMOR; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HLA-A ANTIGENS; HUMANS; INTERFERON-GAMMA; LEUKOCYTES, MONONUCLEAR; MICE; MICE, TRANSGENIC; MOLECULAR SEQUENCE DATA; OLIGOPEPTIDES; OVARIAN NEOPLASMS; RATS; T-LYMPHOCYTES, CYTOTOXIC; T-LYMPHOCYTES, REGULATORY; VACCINATION; VACCINES, SUBUNIT;

EID: 77954888739     PISSN: 15249557     EISSN: None     Source Type: Journal    
DOI: 10.1097/CJI.0b013e3181c1f1e9     Document Type: Article

References (42)

1. King J, Waxman J, Stauss H. Advances in tumour immunotherapy. Qjm. 2008;101:675-683.
2. Pejawar-Gaddy S, Finn OJ. Cancer vaccines: accomplishments and challenges. Crit Rev Oncol Hematol. 2008;67:93-102.
3. Van der Burg SH, Bijker MS, Welters MJ, et al. Improved peptide vaccine strategies, creating synthetic artificial infections to maximize immune efficacy. Adv Drug Deliv Rev. 2006;58:916-930.
4. Kirkwood JM, Tarhini AA, Panelli MC, et al. Next generation of immunotherapy for melanoma. J Clin Oncol. 2008;26:3445-3455.
5. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell. 2000;100:57-70.
6. Mitchell MS. Cancer vaccines, a critical review-part i. Curr Opin Investig Drugs. 2002;3:140-149.
7. Daftarian P, Mansour M, Benoit AC, et al. Eradication of established hpv 16-expressing tumors by a single administration of a vaccine composed of a liposome-encapsulated ctl-t helper fusion peptide in a water-in-oil emulsion. Vaccine. 2006;24:5235-5244.
8. Daftarian PM, Mansour M, Pohajdak B, et al. Rejection of large hpv-16 expressing tumors in aged mice by a single immunization of vaccimax encapsulated ctl/t helper peptides. J Transl Med. 2007;5:26.
9. Mansour M, Pohajdak B, Kast WM, et al. Therapy of established b16-f10 melanoma tumors by a single vaccination of ctl/t helper peptides in vaccimax. J Transl Med. 2007;5:20.
10. Ramakrishna V, Ross MM, Petersson M, et al. Naturally occurring peptides associated with hla-a2 in ovarian cancer cell lines identified by mass spectrometry are targets of hla-a2-restricted cytotoxic t cells. Int Immunol. 2003;15:751-763.
11. Slingluff CL Jr, Yamshchikov G, Neese P, et al. Phase i trial of a melanoma vaccine with gp100 (280 to 288) peptide and tetanus helper peptide in adjuvant: immunologic and clinical outcomes. Clin Cancer Res. 2001;7:3012-3024.
12. Newberg MH, Smith DH, Haertel SB, et al. Importance of MHC class 1 alpha2 and alpha3 domains in the recognition of self and non-self MHC molecules. J Immunol. 1996;156:2473-2480.
13. Peng S, Trimble C, He L, et al. Characterization of hla-a2-restricted hpv-16 e7-specific cd8 (+) t-cell immune responses induced by DNA vaccines in hla-a2 transgenic mice. Gene Ther. 2006;13:67-77.
14. Appay V, Douek DC, Price DA. Cd8+ t cell efficacy in vaccination and disease. Nat Med. 2008;14:623-628.
15. Finn OJ. Cancer immunology. N Engl J Med. 2008;358:2704-2715.
16. Barnett BG, Ruter J, Kryczek I, et al. Regulatory t cells: a new frontier in cancer immunotherapy. Adv Exp Med Biol. 2008;622:255-260.
17. Curiel TJ. Regulatory t cells and treatment of cancer. Curr Opin Immunol. 2008;20:241-246.
18. Roncarolo MG, Bacchetta R, Bordignon C, et al. Type 1 t regulatory cells. Immunol Rev. 2001;182:68-79.
19. Berzofsky JA, Terabe M. Nkt cells in tumor immunity: opposing subsets define a new immunoregulatory axis. J Immunol. 2008;180:3627-3635.
20. Endharti AT, Rifa IMS, Shi Z, et al. Cutting edge: Cd8+cd122+ regulatory t cells produce il-10 to suppress ifn-gamma production and proliferation of cd8+ t cells. J Immunol. 2005;175:7093-7097.
21. Niederkorn JY. Emerging concepts in cd8 (+) t regulatory cells. Curr Opin Immunol. 2008;20:327-331.
22. Terabe M, Berzofsky JA. The role of nkt cells in tumor immunity. Adv Cancer Res. 2008;101:277-348.
23. Kobayashi H, Celis E. Peptide epitope identification for tumorreactive cd4 t cells. Curr Opin Immunol. 2008;20:221-227.
24. Pardoll DM, Topalian SL. The role of cd4+ t cell responses in antitumor immunity. Curr Opin Immunol. 1998;10:588-594.
25. Dunbar PR, Smith CL, Chao D, et al. A shift in the phenotype of melan-a-specific ctl identifies melanoma patients with an active tumor-specific immune response. J Immunol. 2000;165:6644-6652.
26. Lee PP, Yee C, Savage PA, et al. Characterization of circulating t cells specific for tumor-associated antigens in melanoma patients. Nat Med. 1999;5:677-685.
27. Slingluff CL Jr, Petroni GR, Yamshchikov GV, et al. Clinical and immunologic results of a randomized phase ii trial of vaccination using four melanoma peptides either administered in granulocyte-macrophage colony-stimulating factor in adjuvant or pulsed on dendritic cells. J Clin Oncol. 2003;21:4016-4026.
28. Weber J, Sondak VK, Scotland R, et al. Granulocytemacrophagecolony- stimulating factor added to a multipeptide vaccine for resected stage ii melanoma. Cancer. 2003;97:186-200. (Pubitemid 36033878)
29. Mocellin S, Mandruzzato S, Bronte V, et al. Part i: vaccines for solid tumours. Lancet Oncol. 2004;5:681-689.
30. Binaschi M, Bigioni M, Cipollone A, et al. Anthracyclines: selected new developments. Curr Med Chem Anticancer Agents. 2001;1:113-130.
31. Heinzelmann-Schwarz VA, Gardiner-Garden M, Henshall SM, et al. Overexpression of the cell adhesion molecules ddr1, claudin 3, and ep-cam in metaplastic ovarian epithelium and ovarian cancer. Clin Cancer Res. 2004;10:4427-4436.
32. Shimada K, Nakamura M, Ishida E, et al. Prostate cancer antigen-1 contributes to cell survival and invasion though discoidin receptor 1 in human prostate cancer. Cancer Sci. 2008;99:39-45.
33. Levy F, Colombetti S. Promises and limitations of murine models in the development of anticancer t-cell vaccines. Int Rev Immunol. 2006;25:269-295.
34. Depla E, Van der Aa A, Livingston BD, et al. Rational design of a multiepitope vaccine encoding t-lymphocyte epitopes for treatment of chronic hepatitis b virus infections. J Virol. 2008;82:435-450.
35. Brichard VG, Lejeune D. Gsk's antigen-specific cancer immunotherapy programme: pilot results leading to phase iii clinical development. Vaccine. 2007;25(suppl 2): B61-B71.
36. Diaz-Montero CM, Salem ML, Nishimura MI, et al. Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicincyclophosphamide chemotherapy. Cancer Immunol Immunother. 2009;58:49-59.
37. Nagaraj S, Gabrilovich DI. Tumor escape mechanism governed by myeloid-derived suppressor cells. Cancer Res. 2008;68:2561-2563.
38. Kiniwa Y, Miyahara Y, Wang HY, et al. Cd8+ foxp3+ regulatory t cells mediate immunosuppression in prostate cancer. Clin Cancer Res. 2007;13:6947-6958.
39. Peng G, Wang HY, Peng W, et al. Tumor-infiltrating gammadelta t cells suppress t and dendritic cell function via mechanisms controlled by a unique toll-like receptor signaling pathway. Immunity. 2007;27:334-348.
40. Gabrilovich DI, Chen HL, Girgis KR, et al. Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. Nat Med. 1996;2:1096-1103.
41. Piersma SJ, Welters MJ, van der Burg SH. Tumor-specific regulatory t cells in cancer patients. Hum Immunol. 2008;69:241-249.
42. Rabinovich GA, Gabrilovich D, Sotomayor EM. Immunosuppressive strategies that are mediated by tumor cells. Annu Rev Immunol. 2007;25:267-296.